Evaluation of the RSR 3 screen ICA™ and 2 screen ICA™ as screening assays for type 1 diabetes in Sweden

Aim The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Acta diabetologica Ročník 59; číslo 6; s. 773 - 781
Hlavní autoři: Törn, Carina, Vaziri-Sani, Fariba, Ramelius, Anita, Elding Larsson, Helena, Ivarsson, Sten Anders, Amoroso, Marie, Furmaniak, Jadwiga, Powell, Michael, Smith, Bernard Rees
Médium: Journal Article
Jazyk:angličtina
Vydáno: Milan Springer Milan 01.06.2022
Springer Nature B.V
Témata:
Autoantibodies
Autoimmunity
Cation Transport Proteins
Child
Clinical Medicine
Diabetes
Diabetes mellitus (insulin dependent)
Diabetes Mellitus, Type 1
Endocrinology and Diabetes
Endokrinologi och diabetes
Glutamate Decarboxylase
Glutamic acid
Humans
Insulin
Internal Medicine
Klinisk medicin
Medical and Health Sciences
Medicin och hälsovetenskap
Medicine
Medicine & Public Health
Metabolic Diseases
Original
Original Article
Radioimmunoassay
Sweden - epidemiology
Zinc transporter
Sweden
IAA
Sensitivity
Specificity
GADA
IA-2A
ZnT8A
ISSN:1432-5233, 0940-5429, 1432-5233
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Aim The study aim was to evaluate the RSR 3 Screen ICA™ and 2 Screen ICA™ for detection of islet cell autoimmunity in healthy Swedish subjects and patients with newly diagnosed type 1 diabetes (T1D). Methods 3 Screen is designed for combined detection of autoantibodies to glutamic acid decarboxylase (GADA), to the islet antigen IA-2 (IA-2A) and to zinc transporter 8 (ZnT8A), while 2 Screen detects GADA and IA-2A. Serum samples from 100 T1D patients at onset and 200 healthy controls were studied. Results 3 Screen achieved 93% assay sensitivity and 97.5% specificity, while 2 Screen achieved 91% assay sensitivity and 98.5% specificity. Samples were also tested in assays for individual autoantibodies. There was only one 3 Screen positive healthy control sample (0.5%) that was positive for multiple autoantibodies (IA-2A and ZnT8A). In contrast, most of the 93 3 Screen positive patients were positive for multiple autoantibodies with 72% (67/93) positive for both GADA and IA-2A and 57% (53/93) positive for three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients and two healthy controls. Conclusion 3 Screen achieved high sensitivity and specificity, suitable for islet cell autoimmunity screening in a healthy population. In the case of 3 Screen positivity, further assays for GADA, IA-2A and ZnT8A are required to check for multiple autoantibody positivity, a hallmark for progression to T1D. In addition, testing for IAA in children below two years of age is warranted.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Managed by Antonio Secchi.
ISSN:1432-5233
0940-5429
1432-5233
DOI:10.1007/s00592-022-01856-5